Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)-Reference-Cited by-同舟云学术

Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND)

Published:2016-04 Issue:4 Volume:69 Page:720-727
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Schulman Claude,Cornel Erik,Matveev Vsevolod,Tammela Teuvo L.,Schraml Jan,Bensadoun Henri,Warnack Wolfgang,Persad Raj,Salagierski Marek,Gómez Veiga Francisco,Baskin-Bey Edwina,López Beatriz,Tombal Bertrand

Publisher

Elsevier BV

Subject

Urology

Reference23 articles.

1. Adverse effects of androgen deprivation therapy and strategies to mitigate them;Nguyen;Eur Urol,2015

2. Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf. Accessed June 15, 2015.

3. National Institute for Health and Care Excellence (NICE). NICE clinical guideline 175. NICE Web site. https://www.nice.org.uk/guidance/cg175. Updated 2014.

4. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials;Niraula;J Clin Oncol,2013

5. Intermittent endocrine therapy for advanced prostate cancer;Klotz;Cancer,1986

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypofractionated radiation therapy combined with androgen deprivation therapy for clinically node-positive prostate cancer;Radiation Oncology Journal;2024-06-30

2. Hormone Therapy for Advanced Prostate Cancer;Prostate Cancer;2024

3. Comparison of Intermittent and Continuous Androgen Deprivation Therapy in Prostate Cancer Patients: An Up-to-Date Meta-analysis for Urologists and Medical Providers;Urology Practice;2023-09

4. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022;European Urology;2023-03

5. Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?;Human Reproduction Open;2023-01-01